This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
BACKGROUND: High-flow nasal cannula (HFNC) reduces the need for intubation in adult subject with acute respiratory failure. Changes in hypobaric hypoxemia have not been studied for subject with an HFNC in ICUs at altitudes > 2,600 m above sea level. In this study, we investigated the efficacy of HFNC treatment in subjects with COVID-19 at high altitudes. We hypothesized that progressive hypoxemia and the increase in breathing frequency associated with COVID-19 in high altitudes affect the success of HFNC therapy and may also influence the performance of the traditionally used predictors of success and failure.
METHODS: This was a prospective cohort study of subjects >18 y with a confirmed diagnosis of COVID-19–induced ARDS requiring HFNC who were admitted to the ICU. Subjects were followed up during the 28 d of HFNC treatment or until failure.
RESULTS: One hundred and eight subjects were enrolled. At admission to the ICU, FIO2 delivery between 0.5–0.8 (odds ratio 0.38 [95% CI 0.17–0.84]) was associated with a better response to HFNC therapy than oxygen delivery on admission between 0.8–1.0 (odds ratio 3.58 [95% CI 1.56–8.22]). This relationship continued during follow-ups at 2, 6, 12, and 24 h, with a progressive increase in the risk of failure (odds ratio 24 h 13.99 [95% CI 4.32–45.26]). A new cutoff for the ratio of oxygen saturation (ROX) index (ROX ≥ 4.88) after 24 h of HFNC administration was demonstrated to be the best predictor of success (odds ratio 11.0 [95% CI 3.3–47.0]).
CONCLUSIONS: High-altitude subjects treated with HFNC for COVID-19 showed a high risk of respiratory failure and progressive hypoxemia when FIO2 requirements were > 0.8 after 24 h of treatment. In these subjects, personalized management should include continuous monitoring of individual clinical conditions (such as oxygenation indices, with cutoffs adapted to those corresponding to high-altitude cities).
Footnotes
- Correspondence: Daniel Leonardo Molano-Franco MD, Calle 18 N 10–57, Piso 2, Unidad de cuidado Intensivo, Hospital de San José, Bogotá, Colombia. E-mail: dalemofra{at}gmail.com
Dr Masclans discloses a relationship with Fisher & Paykel. The remaining authors have disclosed no conflicts of interest.
- Copyright © 2024 by Daedalus Enterprises
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$30.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
